Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency

Quick Search

Summary

Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is a genetic, metabolic condition in which the body is unable to use certain fats (called very long-chain fatty acids) for energy.1,2 These fatty acids are usually broken down (oxidised) to produce energy through a process called β-oxidation. The VLCAD enzyme is involved in the first step of this β-oxidation process.3 In VLCAD deficiency, the VLCAD enzyme does not work properly, resulting in the body being unable to produce enough energy, especially during times of fasting, illness and exercise, and a build-up of toxic metabolites. This can lead to low blood sugar levels (hypoglycaemia), liver problems, muscle breakdown (rhabdomyolysis), and life-threatening heart complications.

In Australia, VLCAD deficiency is often detected shortly after birth via newborn bloodspot screening (NBS) programs. Additional testing is required to confirm the diagnosis. For individuals who are not screened at birth, VLCAD deficiency is often diagnosed after symptoms develop.

Synonyms and Classifications

Synonyms:2,3 Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency; VLCADD

Universal rare disease classifications provide a common language for recording, reporting and monitoring diseases. Please visit the Rare Disease Classifications page for more information about these internationally recognised classifications.

Symptoms

Symptoms of VLCAD deficiency may vary widely between individuals in severity and onset (age when symptoms develop). The symptoms are often described as the following forms.1-4

Early onset 

Symptoms present early on in life, usually within the first few months or within the first year of life, and are often severe and life-threatening.  Symptoms tend to present as severe metabolic crisis with hypoketotic hypoglycaemia (low ketones and low blood glucose), with babies showing signs of low muscle tone (hypotonia) and extreme tiredness and lack of energy (lethargy). They also often have cardiac arrhythmias (irregular heartbeats), cardiomyopathy (condition that affects the heart muscle, preventing it from pumping blood effectively), an enlarged liver (hepatomegaly) and liver disease. There is a high risk of early death, often associated with the heart issues.

Childhood onset, also known as hepatic or hypoketotic hypoglycemic form 

Symptoms present sometime during childhood as hypoketotic hypoglycaemia (low ketones and low blood glucose) and enlarged liver (hepatomegaly) but very rarely with the cardiac (heart) complications. The risk of early death is lower compared to when there are heart complications.

Later onset

Most commonly observed symptoms of VLCAD. Symptoms present in later childhood or adulthood and mainly affect the muscles. Symptoms may include myalgia (muscle pain), muscle weakness and myoglobinuria (presence of a muscle protein called myoglobin in the urine, which is caused by muscle breakdown known as rhabdomyolysis). Individuals also have exercise intolerance (reduced ability to do physical exercise at a level that would be normally expected). Episodes of the symptoms are usually brought upon (triggered) by prolonged exercise, fasting, extreme temperatures, stress or infections. In some cases, it can lead to kidney failure and early death.

Please speak to your medical team to learn more about the symptoms of this condition.

Disability Impacts

Rare diseases are often serious and progressive, exhibiting a high degree of symptom complexity, leading to significant disability. Majority of the estimated two million Australians living with a rare disease meet the Australian Government’s definition for disability (in accordance to the Australian Public Service Commission and Australian Bureau of Statistics), and many experience severe and permanent disability impacts. If you or someone you care for is experiencing disability-related impacts from a rare condition, please speak with a health or disability professional for advice. Information about relevant disability support can be found at the RARE Portal’s Disability Support Information page.

Cause and Inheritance

VLCAD deficiency is a genetic condition. It is caused by disease-causing genetic changes (variants) in the ACADVL gene on chromosome 17.2,3

All individuals have two copies (alleles) of the ACADVL gene – one copy inherited from each parent. VLCAD deficiency is an autosomal recessive condition, which means both copies of the ACADVL gene must have the disease-causing genetic variants. More information on autosomal recessive inheritance pattern can be found at Centre for Genetics Education: Autosomal recessive inheritance.

If you would like to learn more about the inheritance and impact of this condition, please ask your doctor for a referral to a genetic counsellor. Genetic counsellors are qualified allied health professionals who can provide information and support regarding genetic conditions and testing. More information about genetic counselling can be found at:

Diagnosis

Newborn screening

In Australia, VLCAD deficiency is usually detected via the newborn bloodspot screening (NBS) programs.  Shortly after birth and with parental consent, a nurse or midwife will collect the baby’s blood via a heel prick blood test. The healthcare provider will then send it to a specific laboratory to test for a range of rare conditions, including VLCAD deficiency. If the test results suggest that there is a risk of the baby having one of the screened conditions, laboratory staff will promptly get in touch with healthcare providers. The healthcare providers will then arrange for the baby to have further testing to confirm if the baby actually has the condition. The healthcare providers will also organise for the baby to receive urgent care if required. Depending on your state or territory, parents may or may not receive a notification if the test results are clear. You can find out more about NBS in your state or territory at Australian Government Department of Health, Disability and Ageing: Delivering newborn bloodspot screening programs.

Newborn bloodspot screening is a reliable way to check for certain rare conditions early in life. Although it’s extremely rare, cases can sometimes be missed. If you are concerned your baby may have a condition that they have already been screened for, you should contact a medical professional.

Diagnosis

A diagnosis of VLCAD deficiency may be suspected based on an abnormal result from NBS but additional tests or a clinical examination will be required to confirm a diagnosis. For individuals who are not screened at birth, VLCAD deficiency is often diagnosed after symptoms develop.

Diagnosis of VLCAD deficiency may be made based on clinical evaluation of symptoms, laboratory tests to detect for abnormal acylcarnitine profile in blood samples, and abnormal organic acid pattern in urine samples, and confirmed by genetic testing.2,5

As part of the diagnostic process, doctors may do a differential diagnosis, which is to rule out other conditions that have similar symptoms, such as other long chain fatty oxidation disorders, glycogen storage disorders, mitochondrial myopathies, and other possible causes of rhabdomyolysis.3

Please speak to your medical team to learn more about the available pathways for diagnosis of this condition.

Treatment

There is currently no curative treatment for VLCAD deficiency. Early diagnosis and appropriate management can help reduce the risk of serious life-threatening complications and improve outcomes. 

Hypoketotic hypoglycaemia, cardiac complications and rhabdomyolysis are medical emergencies and should be treated promptly and accordingly.

Management of VLCAD deficiency includes a low-fat diet with medium-chain triglyceride supplementation, avoidance of fasting and regular monitoring.5-8 This may involve frequent feeds and the recommended time between food may differ depending on age and severity. The recommended dietary management also differs between individuals who have symptoms (symptomatic individuals) and those who do not have any symptoms (asymptomatic individuals).6,8 More frequent feeding and supplementation with carbohydrates is often required during time of illness and when there are high energy demands (such as physical exercise). 

Please speak to your medical team to learn more about the possible treatment or management options for your condition. Treatment will depend on an individual’s specific condition and symptoms. It is also important to stay connected to your medical team so that you can be made aware of any upcoming clinical trial opportunities. For many rare diseases, treatment options may be limited. Participation in a clinical trial may provide access to new or emerging therapies.

Clinical Care Team

Healthcare professionals involved in the clinical care of individuals with VLCAD deficiency may include general practitioners (GP), paediatricians, geneticists, metabolic physicians, genetic counsellors, metabolic dietitians, nurses and other health care professionals that are trained to look after people with metabolic conditions. The need for different healthcare professionals may change over a person’s lifetime and extend beyond those listed here. It is recommended that care is coordinated by a metabolic specialist team. 

Clinical care for rare diseases often involves a multidisciplinary team of medical, care and support professionals. Please note that the information provided here is as a guide and that RVA does not necessarily monitor or endorse specific clinics or health experts.

This may not be applicable to all rare diseases but for many, palliative care services may be relevant and useful. Palliative care services are available for people (adults, children and their families) living with a life-limiting illness and is not only for end-of-life care. It can also help at any stage of illness from diagnosis onwards, and will look different for different people. Palliative care services provide assistance, support, resources and tools to help people manage their illness and the symptoms, ease pain, and improve comfort and quality of life. If this is relevant to you and you wish to find out more information about palliative care and how it can help you, please visit:

Clinical Care Guidelines

International Guideline on the Diagnosis, Treatment, and Monitoring of Long‐Chain Fatty Acid Oxidation Disorders (LC‐FAOD) was developed with evidence- and consensus-based methodology by an international multidisciplinary workgroup of 34 members, including clinicians, nurses, dietitians, and patient representatives, from various countries including Australia; published in 2026. Recommendations address diagnosis, dietary management, fasting tolerance, use of medium-chain fat sources, exercise and illness protocols, pregnancy care, and long-term monitoring.

The following guidance is available from international experts outside Australia; however, there may be information that is not relevant or applicable to the Australian context, and may not be up to date:

Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): An evidence- and consensus-based approach (published in 2020) was developed by the Southeast Regional Genetics Network (SERN) and Genetic Metabolic Dietitians International (GMDI) and includes nutrition recommendations for the healthy individual, illness management, supplementation, monitoring, physical activity and management during pregnancy.

Emergency Management

Individuals living with rare diseases may have complex medical issues and disabilities, which are not always visible. It is often useful to refer to their medical history as well as personal information such as a medical card, doctor’s letter, or if available, a rare disease passport, for relevant information.

In addition, individuals, their parents, families and carers often develop extensive expertise on their specific rare disease. It is important to recognise that they can contribute valuable knowledge about their rare condition. Rare diseases often impact individuals differently, so it’s important to consider a person’s lived experience.

Below are some considerations for the emergency management of individuals living with LCHAD deficiency, including when presenting to emergency departments:3

  • individuals are at risk of hypoketotic hypoglycaemia, which is a medical emergency that require immediate treatment.
  • individuals may also be at risk of cardiomyopathy and cardiac failure
  • fasting and high-fat diet are to be avoided
  • individuals should be monitored to ensure they are not dehydrated (as this leads to risk of rhabdomyolysis and acute renal failure)
  • some anaesthetics may be contraindicated
  • metabolic specialist team should be consulted

Research

Research is essential for improving care and finding new treatments for rare diseases. There are specific considerations for participating in rare disease research, including clinical trials. It is important to be mindful of issues such as data privacy, research ethics, consent and differences in research regulations between Australia and other countries. For more information, please visit the RARE Portal’s Considerations for Participating in Health and Medical Research page.
 
For specific information about clinical trials, please visit the RARE Portal’s Information About Clinical Trials page. It is important to remember there may not always be a relevant clinical trial available or currently recruiting participants. In some cases, joining a registry may help connect people with future research opportunities, including clinical trials. A registry is a database of health and other relevant information about people with a particular condition or conditions. Registries can help researchers understand where more research is needed and find people who may want to participate in research, including clinical trials.
 
It is best to discuss your interest in participating in research with your medical team to determine suitability and eligibility.

Rare Disease Organisation(s)

Australian Organisation:

Mito Foundation
Website: https://www.mito.org.au/contact/

The Mito Foundation is the only organisation dedicated to supporting and empowering people impacted by mitochondrial disease (mito) in Australia. It provides resources and support services for people impacted by mito, and their families, while increasing awareness and understanding of this devastating disease. The foundation aims to transform outcomes for the mito community by driving meaningful change and funding essential research into the prevention, diagnosis, treatment and cures of mitochondrial disorders.

International Organisation:

FOD (Fatty Oxidation Disorders) Family Support Group (United States of America)

Website: https://www.fodsupport.org/

Please note that RVA does not monitor or endorse each group/organisation’s operational governance and activities. When engaging with a group, please consider the information on the RARE Portal’s Finding Helpful Peer and Community Supports page.

Lived Experience

VLCAD deficiency varies between individuals, and each person’s experience is unique.

If you would like to share your personal story with RVA, please visit the Rare Voices Australia: Share Your Story page. RVA will consider your story for publishing on our website and inclusion on the RARE Portal.

Support Services and Resources

For information on available government and social services that provide support for individuals with a rare disease, please visit the National and State Services pages.

Mental Health

People living with a rare disease often face unique challenges such as diagnostic delays, misdiagnoses, limited treatment options, and limited access to rare disease specialists and support. These challenges may impact people’s emotional wellbeing and quality of life. Many find it helpful to seek mental health and wellbeing support to cope with ongoing stress and uncertainty. Connecting with people who have shared experiences through a support group may also be helpful. Information about relevant mental health and wellbeing support can be found at:

Other Information

Useful Links for Healthcare Professionals

References

  1. Genetic and Rare Diseases (GARD) Information Center. Very long chain acyl-coa dehydrogenase deficiency. Accessed 8 October 2026. https://rarediseases.info.nih.gov/diseases/5508/very-long-chain-acyl-coa-dehydrogenase-deficiency
  2. Orphanet. Very long chain acyl-CoA dehydrogenase deficiency. Updated February 2014. Accessed 8 October 2026.https://www.orpha.net/en/disease/detail/26793
  3. Leslie N, Saenz-Ayala S. Very long-chain acyl-coenzyme A dehydrogenase deficiency. 2009 [Updated 7 August 2025]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-. https://www.ncbi.nlm.nih.gov/books/NBK6816
  4. National Organization for Rare Disorders (NORD). Very long chain acyl coA dehydrogenase deficiency (LCAD). Updated 14 March 2024. https://rarediseases.org/rare-diseases/very-long-chain-acyl-coa-dehydrogenase-deficiency-lcad/
  5. Al Bandari M, Nagy L, Cruz V et al. Management and outcomes of very long-chain acyl-coA dehydrogenase deficiency (VLCAD deficiency): A retrospective chart review. International Journal of Neonatal Screening. 2024; 10(2), 29. https://doi.org/10.3390/ijns10020029
  6. Evans M, Andresen BS, Nation J, et al. VLCAD deficiency: Follow-up and outcome of patients diagnosed through newborn screening in Victoria. Mol Genet Metab. 2016;118(4):282-7. https://doi.org/10.1016/j.ymgme.2016.05.012
  7. Van Calcar SC, Sowa M, Rohr F, et al. Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): An evidence- and consensus-based approach. Mol Genet Metab. 2020;131(1-2):23-37. https://doi.org/10.1016/j.ymgme.2020.10.001
  8. Grünert SC, Bhattacharya K, Karall D, et al; International LC‐FAOD Guideline Workgroup. International guideline on the diagnosis, treatment, and monitoring of long-chain fatty acid oxidation disorders (LC-FAOD). J Inherit Metab Dis. 2026;49(5):e70251. https://doi.org/10.1002/jimd.70251
Contributors

This page has been developed by Rare Voices Australia (RVA)’s RARE Portal team.

If you are aware of any additional information that may benefit stakeholders with an interest in this page, or if you notice any broken links or inaccurate information, please let us know via the Contribute page.